drugset / Trial / NCT01271452

Safety and Efficacy of Two Types of Botulinum Toxin Type A For the Treatment of Glabellar Lines

NCT01271452

Phase 4 Completed 224 enrolled Allergan
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the safety and efficacy of two different types of botulinum toxin type A for the treatment of glabellar frown lines.

Timeline

Start
2010-09
Primary completion
2011-01
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Botulinum toxin type A Protein / enzyme biologic 20 iu Other
Comparator Botulinum toxin type A Protein / enzyme biologic 30 iu Other

Indications

No indication recorded.